Press Releases Items Per Page 102550 Year None202220212020201920182017201620152014 11-15-2022 Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health 11-14-2022 Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study 11-10-2022 Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update 11-08-2022 Daré Bioscience to Present at the Stifel 2022 Healthcare Conference 11-03-2022 Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022 11-01-2022 Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete 10-17-2022 Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study 10-10-2022 Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive 09-15-2022 Daré Bioscience to Participate in Two Upcoming Conferences 09-06-2022 Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 31
11-15-2022 Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
11-14-2022 Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
11-10-2022 Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
11-03-2022 Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
11-01-2022 Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
10-10-2022 Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
09-06-2022 Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference
